IBJNews

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.

The experimental medicines will be tested in a trial called DIAN TU involving 160 people with a mutation that guarantees they will develop Alzheimer’s at an early age, perhaps as young as 30, the university said in a statement Wednesday.

If the trial is successful, it may lead to those drugs being widely used for people who may have a family history of the disease. Solanezumab slowed the decline in some patients with mild Alzheimer’s and provided no benefit to more advanced patients, Indianapolis-based Lilly announced in August. On Oct. 8, an independent group of scientists confirmed the findings.

“Trying to prevent Alzheimer’s symptoms from ever occurring is a new strategy,” said John C. Morris, the trial’s principal investigator, in Wednesday’s statement. That will be the goal of the research, he said.

Lilly and Roche, based in Basel, Switzerland, have agreed to make their treatments available for the study at no cost, and will support the trial with grants. Another $4.2 million has been given to the investigation from the Alzheimer’s Association, an advocacy group based in Chicago.

The trial will be conducted by Washington University’s unit of the Dominantly Inherited Alzheimer’s Network, or DIAN, an international group of scientists studying rare genetic mutations that cause the disease. The information gathered in these patients may enable better treatment for all dementia patients.

Roche’s gantenerumab binds to clumps of beta amyloid, a protein thought to cause the disease. The drug is thought to help remove the clumps from the brain, and is in a mid- to late-stage company trial that started in 2010. Lilly's solanezumab removes the beta amyloid before it forms plaques.

Another Lilly drug, called a beta secretase inhibitor, is in testing by the company and may be included in the university research as well, according to Wednesday’s statement. That drug is thought to work by reducing the amount of beta amyloid produced in the brain.

The trial, which may start early next year, will test the medicines in inherited early-onset Alzheimer’s patients. The researchers will see if the treatments can prevent the loss of brain function.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Choice between a democrat and a question mark? Take the question mark. We have all seen what the democrats will do.

  2. Its easy to blame workers. What about the Management of the Mill. Its not smart in business to not have a back up plan. Workers are afforded sick days in most cases. Union or not. Whether drunk partying, or a real sickness. Why would you as a businessman/woman not have a rotation of workers incase this happens. This is not an exclusive union protection. If the company can prove bad intentions on the part of any union employee. They can take action. Most CBA's have a 3 strike policy. Just like most Non-union company policies. You should read a CBA sometime. There are protections for companies too. Unions understand that businesses need to make money. If they don't, the union's member won't have a place to work.

  3. My kids play hockey on the North side and we have been very happy with the youth program. More Ice would create more opportunity for kids to pay this great sport. With 3 rinks that would also create more figure skating opportunities. What better gift to give your kids than a sport they will love!

  4. Naah, only Indy place fans were robbed of seeing Zanardi race. CART fans saw his amazing talents just about every weekend. And F1 fans saw him too. Zanardi didn't care he wasn't at Indy, neither do 99.18% of other race fans world wide. And CART fans are quite pleased of the domination of their drivers and owners have had at Indy, in the IRL, and in the current Indycar series....almost 99.18% of the time since 2000 Indy 500. I respect Zanardi, but his life goes on without Indy. Sucks to be you Capt.

  5. So let me get this right: gun permits online are fraud proof, but voting is as easy as 1-2-3.--But at least we agree that someone without a photo ID cannot be trusted with a gun.

ADVERTISEMENT